Psoriatic Arthritis Clinical Trial
Official title:
Prospective Multicentre Follow-up Evaluating Clinical and Radiological Outcomes of Total Shoulder Arthroplasty With Permedica MIRAI Modular Shoulder Prosthesis System - an Observational Study
Verified date | February 2024 |
Source | Permedica spa |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This observational study is conducted in order to evaluate the effectiveness of the primary total shoulder arthroplasty with the Permedica's MIRAI Modular Shoulder Prosthesis System on the general population of patients who are about to undergo this surgery for every indication. Patients requiring a revision shoulder arthroplasty will not be enrolled. The effectiveness will be evaluated in terms of recovery of shoulder function and stability of the prosthetic implant. The incidence of complications, adverse and serious adverse events will also be studied. Additional study aim is to evaluate a medium/long term survival of the prosthesis. The duration of the study per single subject is 5 years.
Status | Active, not recruiting |
Enrollment | 200 |
Est. completion date | July 31, 2025 |
Est. primary completion date | July 31, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - both genders - at least 18 years old of age - undergoing a primary total shoulder arthroplasty with MIRAIĀ® Prosthesis System (anatomic or reverse, stemless or stemmed). - Signed informed consent Exclusion Criteria: - Patients requiring a revision shoulder arthroplasty - Persistent chronic or acute infections and all septic conditions - Persistent osteomyelitis local or systemic - Allergy or hypersensitivity to the substances contained in the materials of the implanted components - Acute or chronic neurological and/or musculoskeletal impairment which compromises the shoulder joint function such as an axillary nerve injury affecting the deltoid muscle - Inadequate bone structure which cannot guarantee stability to the prosthetic components - Several vascular, nerve or muscular disorders, which compromise related extremities - Marked osteoporosis, osteomalacia - Hypotrophy of the periarticular soft tissues - Dysmetabolic diseases such as, for example, kidney failure or systemic diseases - Muscular insufficiency - Active neoplastic or metastatic diseases - Any other clinical or physical condition that can invalidate the surgery, the rehabilitation or the prosthesis stability - Patient unwilling or unable to undergo the rehabilitation or to return to follow-up visits - Women in pregnancy, childbearing potential or breastfeeding - Involvement in other ongoing studies or clinical trial. |
Country | Name | City | State |
---|---|---|---|
Germany | go:h - Gelenkchirurgie Orthopädie: Hannover | Hanover | |
Germany | Krankenhaus Reinbek St. Adolf-Stilt | Reinbek | |
Italy | ULSS 1 Dolomiti - Presidio Ospedaliero Santa Maria del Prato di Feltre | Feltre | |
Switzerland | Orthopädische Klinik Luzern - OKL | Luzern |
Lead Sponsor | Collaborator |
---|---|
Permedica spa |
Germany, Italy, Switzerland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Clinical outcome: Change of shoulder function | Change of "American Shoulder and Elbow Surgeons" (ASES) Score. Total score 0-100 ASES points, 0 = worse pain and functional loss/disability. | 5 years | |
Primary | Clinical outcome: Change of shoulder function | Change of "Disabilities of the Arm, Shoulder and Hand" (DASH) Score. A higher score indicates greater disability. DASH disability/symptom score = [(sum of n responses) - 1]/n x 25, where n is equal to the number of completed responses. | 5 years | |
Primary | Clinical outcome: Change of shoulder function | Change of Constant Score. Total score 0-100 Constant points, 0 = worse outcome and functional loss/disability; 100 = better outcome, shoulder function improvement. | 5 years | |
Primary | Clinical outcome: Change of shoulder function | Change of active Range of Motion (ROM) | 5 years | |
Secondary | Radiological outcome: Radiological implant stability | Presence of Radiolucent Lines and other radiological signs of instability | 5 years | |
Secondary | Radiological outcome: Radiological implant stability | Presence of Radiolucent Lines and other radiological signs of instability | 2 years | |
Secondary | Safety Outcome | Incidence of adverse events and complications | 5 years | |
Secondary | Implant survival rate | Rate of revisions. Survival estimated with Kaplan-Meier method. | 5 years | |
Secondary | Implant survival rate | Implant failures. Survival estimated with Kaplan-Meier method. | 2 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04152759 -
Comparative Study to Evaluate the Pharmacokinetics of BAT2506 vs Simponi® in Healthy Subjects
|
Phase 1 | |
Completed |
NCT03248518 -
Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases
|
N/A | |
Completed |
NCT01925768 -
Safety and Efficacy Study of Apremilast to Treat Psoriatic Arthritis
|
Phase 3 | |
Completed |
NCT01892436 -
Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis
|
Phase 3 | |
Completed |
NCT01212770 -
PALACE 3: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis
|
Phase 3 | |
Completed |
NCT05051943 -
A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
|
||
Completed |
NCT01212757 -
PALACE 2: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis
|
Phase 3 | |
Completed |
NCT03953378 -
CD73+ Th1.17 in Rheumatoid Arthritis and Psoriatic Arthritis
|
||
Recruiting |
NCT02572700 -
Pain Mechanisms and Ultrasonographic Disease Activity in Psoriatic Arthritis
|
||
Completed |
NCT02556034 -
Assessment of Tender & Swollen Joints Count Score Performed by a Rheumatologist And Rheumatology Nurses in Patients With RA and PsA.
|
||
Completed |
NCT02154425 -
A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating Mothers
|
Phase 1 | |
Completed |
NCT02188654 -
Metformin in Psoriatic Arthritis
|
N/A | |
Completed |
NCT02164214 -
Does Etanercept Influence Tweak Modulation of Inflammation During Inflammatory Rheumatisms (Psoriatic Arthritis and Rheumatoid Arthritis)?
|
Phase 3 | |
Completed |
NCT01392326 -
Efficacy at 24 Weeks and Long Term Safety, Tolerability and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Psoriatic Arthritis (PsA)
|
Phase 3 | |
Completed |
NCT01083693 -
Quality of Life Outcomes of HUMIRA in Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS) After Unsustainable Response to Biologicals and Disease Modifying Antirheumatic Drugs
|
N/A | |
Not yet recruiting |
NCT00517101 -
Presence of IBD Specific Antibodies (ASCA, ALCA, ACCA, AMCA) in the Sera of Patients With Spondyloarthropathy
|
N/A | |
Completed |
NCT00133315 -
TNFalfa Blocking Treatment of Spondylarthropathies
|
Phase 4 | |
Completed |
NCT00659412 -
A Placebo-controlled Study With an Extension Examining the Safety and Efficacy of Alefacept in Psoriatic Arthritis
|
Phase 2 | |
Completed |
NCT00946686 -
To Demonstrate the Relative Bioavailability, Parallel Study Of Leflunomide 20 mg Tablets Under Fasting Conditions
|
Phase 1 | |
Not yet recruiting |
NCT06059430 -
Cohort Project of Patients With Inflammatory Rheumatism
|